組み換えタンパク質の世界市場

世界の組み換えタンパク質の市場規模は、2023年の1,324億米ドルから、予測期間中はCAGR 7.5%で推移し、2029年には2,036億米ドルに達すると予測されています。

北米地域は、2023年の502億米ドルから、CAGR 6.7％で推移し、2029年には743億米ドルに達すると予測されています。また、アジア太平洋地域は、2023年の303億米ドルから、CAGR 9.2%で推移し、2029年には507億米ドルに達すると予測されています。

当レポートでは、世界の組み換えタンパク質の市場を調査し、市場概要、市場影響因子および市場機会の分析、新興技術および技術開発の動向、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

• 市場見通し
• 調査範囲
• 市場概要

第2章 市場概要

• 発現宿主システムの種類
• 組み換えタンパク質の作用機序
• アゴニスト
• アンタゴニスト
• 組み換えタンパク質生産における一般的な手順

第3章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会

第4章 新興技術と開発

• 概要
• 新技術
• タンパク質エンジニアリングの進歩
• CRISPRゲノム編集
• 無細胞タンパク質合成

第5章 市場セグメンテーション分析

• セグメンテーションの内訳
• 世界の組み換えタンパク質市場：製品タイプ別
• ホルモン
• 市場規模・予測
• サイトカイン
• 市場規模・予測
• 酵素
• 市場規模・予測
• 抗体
• 市場規模・予測
• 抗原
• 市場規模・予測
• その他
• 市場規模・予測
• 世界の組み換えタンパク質市場：宿主細胞タイプ別
• 細菌宿主細胞
• 市場規模・予測
• 酵母と真菌細胞
• 市場規模・予測
• 哺乳類細胞
• 市場規模・予測
• 昆虫細胞
• 市場規模・予測
• その他
• 市場規模・予測
• 世界の組み換えタンパク質市場：用途別
• 治療薬とワクチン
• 市場規模・予測
• バイオ医療研究
• 市場規模・予測
• 診断
• 市場規模・予測
• 地理的内訳
• 世界の組み換えタンパク質市場：地域別
• 北米
• 欧州
• アジア太平洋
• その他の地域

第6章 競合情報

• 競合情勢
• M&A分析
• 臨床試験活動

第7章 組み換えタンパク質市場におけるESGの視点

• 組み換えタンパク質市場における持続可能性
• ESGデータの理解
• 環境パフォーマンス
• 社会的パフォーマンス
• ガバナンスパフォーマンス
• BCCからの総論

第8章 付録

• 調査手法
• 出典
• 頭字語
• 企業プロファイル
• AMGEN INC.
• BAYER AG
• F. HOFFMANN-LA ROCHE LTD.
• LILLY
• MERCK KGAA
• NOVO NORDISK A/S
• PFIZER INC.
• SANDOZ GROUP AG
• SANOFI
• TAKEDA PHARMACEUTICAL CO. LTD.

List of Tables

• Summary Table : Global Market for Recombinant Proteins, by Region, Through 2029
• Table 1 : Comparison of Different Protein Expression Host Systems
• Table 2 : R&D Expenditures of Key Biopharmaceutical Companies, 2023
• Table 3 : Global Market for Recombinant Proteins, by Product Type, Through 2029
• Table 4 : Global Market for Recombinant Hormone Proteins, by Region, Through 2029
• Table 5 : Global Market for Recombinant Cytokine Proteins, by Region, Through 2029
• Table 6 : Global Market for Recombinant Enzyme Proteins, by Region, Through 2029
• Table 7 : Global Market for Recombinant Antibody Proteins, by Region, Through 2029
• Table 8 : Global Market for Recombinant Antigen Proteins, by Region, Through 2029
• Table 9 : Global Patient Population Diagnosed with Bleeding Disorders
• Table 10 : Global Market for Other Recombinant Proteins, by Region, Through 2029
• Table 11 : Global Market for Recombinant Proteins, by Host Cell Type, Through 2029
• Table 12 : Global Market for Recombinant Proteins from Bacterial Host Cells, by Region, Through 2029
• Table 13 : Global Market for Recombinant Proteins from Yeast and Fungi Host Cells, by Region, Through 2029
• Table 14 : Global Market for Recombinant Proteins from Mammalian Host Cells, by Region, Through 2029
• Table 15 : Global Market for Recombinant Proteins from Insect Host Cells, by Region, Through 2029
• Table 16 : Global Market for Recombinant Proteins from Other Host Cells, by Region, Through 2029
• Table 17 : Global Market for Recombinant Proteins, by Application, Through 2029
• Table 18 : Therapeutic Applications of Recombinant Proteins, by Product Type
• Table 19 : Global Market for Recombinant Proteins for Therapeutic and Vaccine Applications, by Region, Through 2029
• Table 20 : Global Market for Recombinant Proteins for Biomedical Research, by Region, Through 2029
• Table 21 : Global Market for Recombinant Proteins for Diagnostics, by Region, Through 2029
• Table 22 : Global Market for Recombinant Proteins, by Region, Through 2029
• Table 23 : North American Market for Recombinant Proteins, by Product Type, Through 2029
• Table 24 : North American Market for Recombinant Proteins, by Host Cell Type, Through 2029
• Table 25 : North American Market for Recombinant Proteins, by Application, Through 2029
• Table 26 : North American Market for Recombinant Proteins, by Country, Through 2029
• Table 27 : European Market for Recombinant Proteins, by Product Type, Through 2029
• Table 28 : European Market for Recombinant Proteins, by Host Cell Type, Through 2029
• Table 29 : European Market for Recombinant Proteins, by Application, Through 2029
• Table 30 : European Market for Recombinant Proteins, by Country, Through 2029
• Table 31 : Asia-Pacific Market for Recombinant Proteins, by Product Type, Through 2029
• Table 32 : Asia-Pacific Market for Recombinant Proteins, by Host Cell Type, Through 2029
• Table 33 : Asia-Pacific Market for Recombinant Proteins, by Application, Through 2029
• Table 34 : Asia-Pacific Market for Recombinant Proteins, by Country, Through 2029
• Table 35 : RoW Market for Recombinant Proteins, by Product Type, Through 2029
• Table 36 : RoW Market for Recombinant Proteins, by Host Cell Type, Through 2029
• Table 37 : RoW Market for Recombinant Proteins, by Application, Through 2029
• Table 38 : Top Recombinant Protein Drug Developers, 2023
• Table 39 : Major Strategic Alliances in the Recombinant Proteins Industry, 2022-2024
• Table 40 : Technology Driven Partnerships and Acquisitions in the Recombinant Protein Industry, 2023
• Table 41 : Select Recombinant Protein Therapeutics in Phase 3 Clinical Trials, 2023
• Table 42 : Recombinant Protein Therapeutics in Phase 1 and 2 Clinical Trials, 2023
• Table 43 : Recombinant Protein Therapeutics in Phase 4 and Observational Clinical Trials, 2023
• Table 44 : Select Active Patents of Key Companies, 2020-2023
• Table 45 : ESG Rankings for Major Recombinant Protein Drug Companies, 2023*
• Table 46 : ESG: Environmental Overview
• Table 47 : ESG: Social Factors Overview
• Table 48 : ESG: Governance Overview
• Table 49 : Report Sources
• Table 50 : Glossary of Terms Used in the Recombinant Proteins Market
• Table 51 : Amgen Inc.: Company Snapshot
• Table 52 : Amgen Inc.: Financial Performance, FY 2022 and 2023
• Table 53 : Amgen Inc.: Product Portfolio
• Table 54 : Amgen Inc.: News/Key Developments, 2022 and 2023
• Table 55 : Bayer AG: Company Snapshot
• Table 56 : Bayer AG: Financial Performance, FY 2022 and 2023
• Table 57 : Bayer AG: Product Portfolio
• Table 58 : Bayer AG: News/Key Developments, 2023
• Table 59 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 60 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
• Table 61 : F. Hoffmann-La Roche Ltd.: Product Portfolio
• Table 62 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023
• Table 63 : Lilly: Company Snapshot
• Table 64 : Lilly: Financial Performance, FY 2022 and 2023
• Table 65 : Lilly: Product Portfolio
• Table 66 : Lilly: News/Key Developments, 2023
• Table 67 : Merck KGaA: Company Snapshot
• Table 68 : Merck KGaA: Financial Performance, FY 2022 and 2023
• Table 69 : Merck KGaA: Product Portfolio
• Table 70 : Merck KGaA: News/Key Developments, 2022 and 2023
• Table 71 : Novo Nordisk A/S: Company Snapshot
• Table 72 : Novo Nordisk A/S: Financial Performance, FY 2022 and 2023
• Table 73 : Novo Nordisk A/S: Product Portfolio
• Table 74 : Novo Nordisk A/S: News/Key Developments, 2023 and 2024
• Table 75 : Pfizer Inc.: Company Snapshot
• Table 76 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
• Table 77 : Pfizer Inc.: Product Portfolio
• Table 78 : Pfizer Inc.: News/Key Developments, 2023
• Table 79 : Sandoz Group AG: Company Snapshot
• Table 80 : Sandoz Group AG: Financial Performance, FY 2022 and 2023
• Table 81 : Sandoz Group AG: Product Portfolio
• Table 82 : Sandoz Group AG: News/Key Developments, 2023
• Table 83 : Sanofi: Company Snapshot
• Table 84 : Sanofi: Financial Performance, FY 2022 and 2023
• Table 85 : Sanofi: Product Portfolio
• Table 86 : Sanofi: News/Key Developments, 2022-2024
• Table 87 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
• Table 88 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2021 and 2022
• Table 89 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
• Table 90 : Takeda Pharmaceutical Co. Ltd.: Key Developments, 2022 and 2023

List of Figures

• Summary Figure : Global Market Shares of Recombinant Proteins, by Region, 2023
• Figure 1 : Basic Steps Involved in Recombinant Protein Production
• Figure 2 : Market Dynamics of Recombinant Proteins
• Figure 3 : Global Biopharmaceutical R&D Expenditures, 2020-2026
• Figure 4 : Applications of Recombinant Antibodies
• Figure 5 : Advantages and Disadvantages of Continuous Manufacturing
• Figure 6 : Global Market Shares of Recombinant Proteins, by Product Type, 2023
• Figure 7 : Global Market for Recombinant Hormone Proteins, 2021-2029
• Figure 8 : Global Market for Recombinant Hormone Proteins, by Region, 2021-2029
• Figure 9 : Global Market for Recombinant Cytokine Proteins, 2021-2029
• Figure 10 : Global Market for Recombinant Cytokine Proteins, by Region, 2021-2029
• Figure 11 : Global Market for Recombinant Enzyme Proteins, 2021-2029
• Figure 12 : Global Market for Recombinant Enzyme Proteins, by Region, 2021-2029
• Figure 13 : Advantages of Recombinant Antibodies
• Figure 14 : Global Market for Recombinant Antibody Proteins, 2021-2029
• Figure 15 : Global Market for Recombinant Antibody Proteins, by Region, 2021-2029
• Figure 16 : Global Market for Recombinant Antigen Proteins, 2021-2029
• Figure 17 : Global Market for Recombinant Antigen Proteins, by Region, 2021-2029
• Figure 18 : Global Market for Other Recombinant Proteins, 2021-2029
• Figure 19 : Global Market for Other Recombinant Proteins, by Region, 2021-2029
• Figure 20 : Global Market Shares of Recombinant Proteins, by Host Cell Type, 2023
• Figure 21 : Global Market for Recombinant Proteins from Bacterial Host Cells, 2021-2029
• Figure 22 : Global Market for Recombinant Proteins from Yeast and Fungi Host Cells, 2021-2029
• Figure 23 : Global Market for Recombinant Proteins from Mammalian Host Cells, 2021-2029
• Figure 24 : Global Market for Recombinant Proteins from Insect Host Cells, 2021-2029
• Figure 25 : Global Market for Recombinant Proteins from Other Host Cells, 2021-2029
• Figure 26 : Global Market Shares of Recombinant Proteins, by Application, 2023
• Figure 27 : Global Market for Recombinant Proteins for Therapeutic and Vaccine Applications, 2021-2029
• Figure 28 : Global Market for Recombinant Proteins for Therapeutic and Vaccine Applications, by Region, 2021-2029
• Figure 29 : Global Market for Recombinant Proteins for Biomedical Research, 2021-2029
• Figure 30 : Global Market for Recombinant Proteins for Biomedical Research, by Region, 2021-2029
• Figure 31 : Global Market for Recombinant Proteins for Diagnostics, 2021-2029
• Figure 32 : Global Market for Recombinant Proteins for Diagnostics, by Region, 2021-2029
• Figure 33 : Global Market for Recombinant Proteins, by Region, 2021-2029
• Figure 34 : North American Market Shares of Recombinant Proteins, by Country, 2023
• Figure 35 : European Market Shares of Recombinant Proteins, by Country, 2023
• Figure 36 : Asia-Pacific Market Shares of Recombinant Proteins, by Country, 2023
• Figure 37 : Key ESG Metrics of Recombinant Protein Companies
• Figure 38 : Amgen Inc.: Revenue Shares, by Product, FY 2023
• Figure 39 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2023
• Figure 40 : Bayer AG: Revenue Shares, by Business Unit, FY 2023
• Figure 41 : Bayer AG: Revenue Shares, by Country/Region, FY 2023
• Figure 42 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2023
• Figure 43 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2023
• Figure 44 : Lilly: Revenue Shares, by Business Unit, FY 2023
• Figure 45 : Lilly: Revenue Shares, by Country/Region, FY 2023
• Figure 46 : Merck KGaA: Revenue Shares, by Business Unit, FY 2023
• Figure 47 : Merck KGaA: Revenue Shares, by Country/Region, FY 2023
• Figure 48 : Novo Nordisk A/S: Revenue Shares, by Business Unit, FY 2023
• Figure 49 : Novo Nordisk A/S: Revenue Shares, by Country/Region, FY 2023
• Figure 50 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2023
• Figure 51 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2023
• Figure 52 : Sandoz Group AG: Revenue Shares, by Business Unit, FY 2023
• Figure 53 : Sandoz Group AG: Revenue Shares, by Country/Region, FY 2023
• Figure 54 : Sanofi: Revenue Shares, by Business Unit, FY 2023
• Figure 55 : Sanofi: Revenue Shares, by Country/ Region, FY 2023
• Figure 56 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Business Unit, FY 2022
• Figure 57 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Country/Region, FY 2022

The global market for recombinant proteins is estimated to increase from $132.4 billion in 2023 to reach $203.6 billion by 2029, at a compound annual growth rate (CAGR) of 7.5% from 2024 through 2029.

The North American market for recombinant proteins is estimated to increase from $50.2 billion in 2023 to reach $74.3 billion by 2029, at a CAGR of 6.7% from 2024 through 2029.

The Asia-Pacific market for recombinant proteins is estimated to increase from $30.3 billion in 2023 to reach $50.7 billion by 2029, at a CAGR of 9.2% from 2024 through 2029.

Report Scope

This report covers the current and future global market for recombinant proteins, including a detailed analysis of the market's drivers, restraints and opportunities. The report also covers market projections for 2029, the market's competitive environment and companies' pipeline activities. The report delivers market estimates and forecasts for recombinant proteins categorized according to product type, host cell type, application, and region. Based on product type the market is segmented into hormones, cytokines, enzymes, antigens, antibodies, and others. Based on the host cell type, recombinant proteins are categorized as mammalian, insect, yeast and fungi, bacterial, and other cell types. The market is segmented by application into therapeutics and vaccines, biomedical research, and diagnostics. The report includes the company profiles of the key players, with detailed information about their business segments, financials, product portfolios, and recent developments. The report does not cover proteins produced through hybridoma techniques. The report also excludes COVID-19 vaccines based on recombinant technology.

By geographical region, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. Regional analysis is further broken down by country as follows: North America-the U.S. and Canada; Europe-Germany, the U.K., France, Italy, and the Rest of Europe; Asia-Pacific-China, Japan, India, and the Rest of Asia-Pacific. For market estimates, data have been provided for 2021 and 2022 as the historic years, 2023 as the base year, and a forecast through 2029.

Report Includes

• 45 data tables and 46 additional tables
• Analysis of the global market for recombinant proteins
• Analyses of the global market trends, with market revenue data for 2022, estimates for 2023, forecasts for 2024 and projected CAGRs through 2029
• Discussion of the market drivers, restraints and opportunities
• Estimate of the current market size and revenue prospects, along with a market share analysis by product (protein type), host cell type, application and region
• Facts and figures pertaining to the market dynamics, current and emerging technologies, regulatory scenario, and the expected impact of macroeconomic factors
• Overview of sustainability and ESG trends, with a focus on consumer attitudes, companies' ESG score rankings and their ESG practices
• Analysis of recent patents and pipeline activity
• A look at the industry structure, including companies' market shares, M&A activity and venture funding
• Company profiles of major players within the industry, including Novo Nordisk A/S, Lilly, Sanofi, and Amgen Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Types of Expression Host Systems
• Mechanism of Action of Recombinant Proteins
• Agonists
• Antagonists
• Common Steps Involved in Recombinant Protein Production

Chapter 3 Market Dynamics

• Drivers
• Growing R&D Investments in Biopharmaceuticals
• Increasing Demand for Non-Hybridoma Techniques
• Restraints
• High Production Costs
• Post-Translational Modifications and Protein Stability
• Opportunities
• Diagnostic and Therapeutic Applications of Recombinant Antibodies
• Continuous Manufacturing and Improving Product Yields

Chapter 4 Emerging Technologies and Developments

• Overview
• Emerging Technologies
• Protein-Engineering Advances
• CRISPR Genome Editing
• Cell-Free Protein Synthesis

Chapter 5 Market Segmentation Analysis

• Segmentation Breakdown
• Global Market for Recombinant Proteins, by Product Type
• Hormones
• Market Size and Forecast
• Cytokines
• Market Size and Forecast
• Enzymes
• Market Size and Forecast
• Antibodies
• Market Size and Forecast
• Antigens
• Market Size and Forecast
• Others
• Market Size and Forecast
• Global Market for Recombinant Proteins, by Host Cell Type
• Bacterial Host Cells
• Market Size and Forecast
• Yeast and Fungi Cells
• Market Size and Forecast
• Mammalian Cells
• Market Size and Forecast
• Insect Cells
• Market Size and Forecast
• Other Cells
• Market Size and Forecast
• Global Market for Recombinant Proteins, by Application
• Therapeutics and Vaccines
• Market Size and Forecast
• Biomedical Research
• Market Size and Forecast
• Diagnostics
• Market Size and Forecast
• Geographic Breakdown
• Global Market for Recombinant Proteins, by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 6 Competitive Intelligence

• Competitive Landscape
• M&A Analysis
• Clinical Trial Activities

Chapter 7 ESG Perspective in the Recombinant Proteins Market

• Sustainability in the Recombinant Proteins Market
• Understanding the ESG Data
• Environmental Performance
• Social Performance
• Governance Performance
• Concluding Remarks from BCC

Chapter 8 Appendix

• Methodology
• Sources
• Acronyms
• Company Profiles
• AMGEN INC.
• BAYER AG
• F. HOFFMANN-LA ROCHE LTD.
• LILLY
• MERCK KGAA
• NOVO NORDISK A/S
• PFIZER INC.
• SANDOZ GROUP AG
• SANOFI
• TAKEDA PHARMACEUTICAL CO. LTD.